Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 05, 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase price of 1,192.44 pence per share.
Material Changes
- Share Repurchase: The Company purchased 1,132,880 Ordinary shares of 25 pence each on November 05, 2008.
- Treasury Holdings: Following the cancellation of the repurchased shares, the Company holds 474,194,158 shares in Treasury, representing 9.09% of total voting rights.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) is 5,214,212,097.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,214,212,097) for calculating disclosure thresholds under Financial Services Authority rules.
- Confirm the Treasury share count (474,194,158) and its impact on total voting rights (9.09%).
- Note that this filing is a routine disclosure of a share buyback and does not contain operational or financial performance data.